# Heartflow

> Heartflow is a Silicon Valley medical technology company that uses AI and computational fluid dynamics to turn a standard coronary CT scan into a personalized, color-coded 3D model of a patient's heart. Its FFRCT, Plaque and RoadMap analyses help cardiologists diagnose and manage coronary artery disease non-invasively, reducing the need for invasive angiograms. Founded in 2007 and headquartered in San Francisco, Heartflow has analyzed hundreds of thousands of patients across more than 1,500 U.S. hospitals and went public on the Nasdaq (HTFL) in August 2025.

- **Founded:** 2007
- **Headquarters:** San Francisco, California, United States
- **Founders:** Charles Taylor (Co-founder (former CTO); engineer, Center for Computational Medicine, UT Austin), Christopher Zarins (Co-founder; vascular surgeon)
- **Team size:** ~630 employees
- **Products:** Heartflow FFRCT Analysis, Heartflow RoadMap Analysis, Heartflow Plaque Analysis, Heartflow One
- **Notable:** First AI-enabled technology included in ACC and AHA clinical practice guidelines for heart disease (2021)., Assessed coronary artery disease in over 400,000 patients; surpassed 250,000-patient FFRCT milestone in 2024., Deployed at more than 1,500 U.S. hospitals.

## Products & services

- **Heartflow FFRCT Analysis** — Uses deep learning and computational fluid dynamics to build a personalized 3D model of the coronary arteries from CCTA images and calculate blood flow (fractional flow reserve), pinpointing clinically significant narrowings non-invasively. The commercial foundation of the company, representing ~98% of revenue.
- **Heartflow RoadMap Analysis** — Automatically delivers visualization and quantification of the location and severity of anatomic narrowings in the coronary arteries to the interpreting cardiologist or radiologist for every acceptable CCTA, streamlining interpretation and workflow.
- **Heartflow Plaque Analysis** — Delivers insight into the type, volume and distribution of coronary plaque. The Next Generation platform (FDA 510(k) cleared 2025) adds an updated algorithm, expanded nomogram and 3D color-coded visualization.
- **Heartflow One** — The unified cloud platform combining RoadMap, FFRCT and Plaque analyses into a single AI-enabled coronary artery disease assessment workflow.

## Achievements

- First AI-enabled technology included in ACC and AHA clinical practice guidelines for heart disease (2021).
- Assessed coronary artery disease in over 400,000 patients; surpassed 250,000-patient FFRCT milestone in 2024.
- Deployed at more than 1,500 U.S. hospitals.
- Completed a ~$364M Nasdaq IPO (HTFL) in August 2025, pricing above the range.
- FDA 510(k) clearance and launch of Next Generation Plaque Analysis platform (2025).
- Q3 2025 revenue up 41% YoY to $46.3M with global cases up 48%.

## Latest updates

- **2025-12** — New analyses of over 90,000 patients show Heartflow FFRCT Analysis delivers prognostic power and significant cost savings in coronary artery disease.
- **2025-12** — Heartflow Plaque Analysis supported by scientific statements from the ACC and AHA for personalized management of suspected CAD.
- **2025-11** — Q3 2025 results: revenue $46.3M, up 41% YoY; global revenue cases up 48%; full-year 2025 revenue guidance ~$173M.
- **2025-09** — FDA 510(k) clearance and launch of the Next Generation Heartflow Plaque Analysis platform with 3D color-coded visualization.
- **2025-08** — Heartflow completed its upsized Nasdaq IPO (HTFL), raising ~$364.2M gross at $19/share.
- **2025-02** — Company unveiled a new brand identity and 'bold new vision' for coronary artery disease management.

## Links

- Website: https://heartflow.com
- LinkedIn: https://www.linkedin.com/company/heartflow-inc
- Twitter/X: https://twitter.com/heartflow
- YouTube: https://www.youtube.com/@Heartflow
- Facebook: https://facebook.com/HeartFlow-832414017101512/

---

Profile page: https://yespress.io/heartflow
Published by YesPress — https://yespress.io
Last updated: 2026-07-14